

# Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol<sup>®</sup> Cyclo<sup>™</sup>, at WORLDSymposium 2021

**Gainesville, FL – (Businesswire) – January 26, 2021 -- [Cyclo Therapeutics, Inc.](#)** (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol<sup>®</sup> Cyclo<sup>™</sup>) in the treatment of Niemann-Pick Disease Type C (NPC), today announced details for the Company’s upcoming presentations at the [17<sup>th</sup> Annual WORLDSymposium 2021](#), a leading medical and scientific conference for professionals working to advance understanding and treatments for lysosomal storage diseases, including NPC. The conference will be held virtually between February 8–12, 2021.

Summarized below are the details for ePoster titles that have been selected for oral presentation as well as the platform presentation. The full WORLDSymposium agenda is now available online at the conference [website](#). Information from ePosters and the platform presentation and are under embargo until 2:30 PM EST on Monday, February 8, 2021, and the start of the presentation, respectively. Once the slides for the orally presented posters are made public, they will be available on the Company’s website in the [Presentations](#) section.

## **Platform Presentation**

**Title:** *Update on safety and efficacy results for Phase I/II trial of hydroxypropyl beta-cyclodextrin (HPBCD) administered intravenously in patients with Niemann-Pick disease type C1*

**Date and Time:** Tuesday, February 9, 2021, at 1:24 PM

**Presenter:** Julian Raiman, MD, Birmingham Women’s and Children’s Hospital, United Kingdom, and Principal Investigator

The presentation will be followed by a live Q&A session open to those registered to attend the virtual conference, beginning at 1:48 PM on Tuesday, February 9, 2021.

## **ePoster Presentations**

**Poster #209:** *Update on safety and efficacy results for Phase I/II trial of hydroxypropyl beta-cyclodextrin (HPBCD) administered intravenously in patients with Niemann-Pick disease type C*

**Date and Time:** Tuesday, February 9, 2021, between 2:30 – 3:30 PM

**Session:** Translational Research Abstracts

**Presenter:** Julian Raiman, MD, Birmingham Women’s and Children’s Hospital, United Kingdom, Principal Investigator

**Poster #095:** *Update on Phase I study to evaluate the single- and multiple-dose pharmacokinetics of intravenous hydroxypropyl beta-cyclodextrin (HPBCD) in patients with Niemann-Pick disease type C (NPC-1) and the effects of dosing upon biomarkers of NPC disease*

**Date and Time:** Wednesday, February 10, 2021, between 2:30 – 3:30 PM

**Session:** Translational Research Abstracts

**Presenter:** Caroline Hastings, MD, UCSF Benioff Children’s Hospital Oakland, California, and Principal Investigator

### **About *WORLDSymposium***<sup>™</sup>

*WORLDSymposium*<sup>™</sup> is an annual research conference dedicated to lysosomal diseases. WORLD is an acronym that stands for We’re Organizing Research on Lysosomal Diseases. Since its inception as a small group of passionate researchers in 2002, *WORLDSymposium* has grown to an international research conference that attracts over 2000 participants from more than 50 countries around the globe. For more information, please visit: [worldsymposia.org](http://worldsymposia.org).

### **About *Cyclo Therapeutics***

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol<sup>®</sup> Cyclo<sup>™</sup>, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov [NCT02939547](https://clinicaltrials.gov/ct2/show/study/NCT02939547), [NCT02912793](https://clinicaltrials.gov/ct2/show/study/NCT02912793) and [NCT02912793](https://clinicaltrials.gov/ct2/show/study/NCT02912793)). The company is planning an early phase clinical trial using Trappsol<sup>®</sup> Cyclo<sup>™</sup> intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease ([NCT03624842](https://clinicaltrials.gov/ct2/show/study/NCT03624842)). Additional indications for the active ingredient in Trappsol<sup>®</sup> Cyclo<sup>™</sup> are in development. For additional information, visit the company’s website: [www.cyclotherapeutics.com](http://www.cyclotherapeutics.com)

### **Safe Harbor Statement**

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable

contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

***Investor Contact:***

JTC Team, LLC

Jenene Thomas

(833) 475-8247

[CYTH@jtcir.com](mailto:CYTH@jtcir.com)